Cargando…

Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs

The association between cancer and a hypercoagulatory environment is well described. Thrombotic complications serve not only as a major mortality risk but the underlying molecular structure and function play significant roles in enhancing tumour progression, which is defined as the tumour’s capacity...

Descripción completa

Detalles Bibliográficos
Autores principales: Xulu, Kutlwano R., Augustine, Tanya N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784118/
https://www.ncbi.nlm.nih.gov/pubmed/36558983
http://dx.doi.org/10.3390/ph15121532
_version_ 1784857734192037888
author Xulu, Kutlwano R.
Augustine, Tanya N.
author_facet Xulu, Kutlwano R.
Augustine, Tanya N.
author_sort Xulu, Kutlwano R.
collection PubMed
description The association between cancer and a hypercoagulatory environment is well described. Thrombotic complications serve not only as a major mortality risk but the underlying molecular structure and function play significant roles in enhancing tumour progression, which is defined as the tumour’s capacity to survive, invade and metastasise, amongst other hallmarks of the disease. The use of anticoagulant or antiplatelet drugs in cardiovascular disease lessens thrombotic effects, but the consequences on tumour progression require interrogation. Therefore, this review considered developments in the management of platelet activation pathways (thromboxane, ADP and thrombin), focusing on the use of Aspirin, Clopidogrel and Atopaxar, and their potential impacts on tumour progression. Published data suggested a cautionary tale in ensuring we adequately investigate not only drug–drug interactions but also those unforeseen reciprocal interactions between drugs and their targets within the tumour microenvironment that may act as selective pressures, enhancing tumour survival and progression.
format Online
Article
Text
id pubmed-9784118
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97841182022-12-24 Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs Xulu, Kutlwano R. Augustine, Tanya N. Pharmaceuticals (Basel) Review The association between cancer and a hypercoagulatory environment is well described. Thrombotic complications serve not only as a major mortality risk but the underlying molecular structure and function play significant roles in enhancing tumour progression, which is defined as the tumour’s capacity to survive, invade and metastasise, amongst other hallmarks of the disease. The use of anticoagulant or antiplatelet drugs in cardiovascular disease lessens thrombotic effects, but the consequences on tumour progression require interrogation. Therefore, this review considered developments in the management of platelet activation pathways (thromboxane, ADP and thrombin), focusing on the use of Aspirin, Clopidogrel and Atopaxar, and their potential impacts on tumour progression. Published data suggested a cautionary tale in ensuring we adequately investigate not only drug–drug interactions but also those unforeseen reciprocal interactions between drugs and their targets within the tumour microenvironment that may act as selective pressures, enhancing tumour survival and progression. MDPI 2022-12-09 /pmc/articles/PMC9784118/ /pubmed/36558983 http://dx.doi.org/10.3390/ph15121532 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Xulu, Kutlwano R.
Augustine, Tanya N.
Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
title Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
title_full Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
title_fullStr Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
title_full_unstemmed Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
title_short Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
title_sort targeting platelet activation pathways to limit tumour progression: current state of affairs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784118/
https://www.ncbi.nlm.nih.gov/pubmed/36558983
http://dx.doi.org/10.3390/ph15121532
work_keys_str_mv AT xulukutlwanor targetingplateletactivationpathwaystolimittumourprogressioncurrentstateofaffairs
AT augustinetanyan targetingplateletactivationpathwaystolimittumourprogressioncurrentstateofaffairs